

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Complete if Known
Application Number	10/584,445			
Filing Date	June 22, 2006			
First Named Inventor	Elie LEVERD			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	3493-0170PUS1			

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-4,923,876-A	05-08-1990	Francis, et al.	
	AB*	US-6,127,377-A	10-03-2000	Duflos, et al.	
	AC*	US-4,307,100-A	12-22-1981	Langlois, et al.	
	AD*	US-4,684,638-A	08-04-1987	Nagy, et al.	
	AE*	US-5,620,985	04-15-1997	Jacquesy, et al.	
	AF*	US-5,397,784	03-14-1995	Gazdag et al.	
	AG*	US-4,619,935	10-26-1986	Robison	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number <sup>5</sup> -Kind Code <sup>6</sup> (if known)				
	BA	EP-0710240-B1	12-18-1996	claims only/not in English		
	BB	EP-2653009-A1	05-10-1991			
	BC	CA-2001643-A	06-23-1990	lined out refs not in English		
	BD	EP-0298192-A1	01-11-1989			
	BE	EP-0317401-A1	05-24-1989			
	BF	GB-2020180-A	11-14-1979			
	BG	FR-2620069-A1	05-10-1991			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). \* See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
	CA	Hill B T et al: European Journal of Cancer (Oxford England: 1990) Mar 1999, Vol. 35, No 3, Pages 512-550, XP002297710.	
	CB	Hill Bridget T: September 2001, Current Pharmaceutical Design, Vol 7, pages 1199-1212, XP002297712	
	CC	Kruczynski A et al: Cancer Chemother and Pharmacol, 1998, DE, Vol 41, 1998, pages 437-447, XP002297711.	
	CD	B Pourroy et al: Cancer Res 2006; 66: (6) March 15, 2006, pages 3256-3263.	
	CE	B Pourroy et al: Pro Amer Assoc Cancer Res 2005;46: 3434.	
	CF	Pourroy et al: Proc Amer Assoc Cancer Res 2006, 47 (abstract from the 97th AACR Annual Meeting D.C., 2006)	
	CG	SE Holwell et al: British Journal of Cancer (2001) 84(2), pages 290-295.	
	CH	Kruczynski et al: Proc Amer Assoc Cancer Res, Vol 44:119, March 2003	
	CI	Kruczynski et al: AACR-NCI-EORTC International Conference, Molecular Targets and Cancer	

Examiner Signature	Date Considered
--------------------	-----------------

Birch, Stewart, Kolasch &amp; Birch, LLP

ADP/ma

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/



PTO/SB/08AB (09-06)  
Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/584,445
		Filing Date	June 22, 2006
		First Named Inventor	Elie LEVERD
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	3493-0170PUS1
Sheet	2	of	2

		Therapeutics, Abstract B22; 9: 126, 2003	
	CJ	Kruczynski et al: Proc Amer Cancer Res, Vol 43 March 2002, page 268, No. 1332	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Timothy Thomas/	Date Considered	04/15/2008
--------------------	------------------	-----------------	------------

Birch, Stewart, Kolesch & Birch, LLP

ADM/ma

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/